REBEKAH MALDONADO: Open Payments
NPI 1740756279 · MENIFEE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$464 in 25 payments from 13 companies in 2025. Trend: 2023 $139 · 2024 $98 · 2025 $464
Food & beverage: $464
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $153 |
| Novo Nordisk Inc | 3 | $75 |
| Lilly USA, LLC | 2 | $34 |
| Astellas Pharma US Inc | 1 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $28 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Dexcom, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| PFIZER INC. | 1 | $16 |
Products named: AIRSUPRA, JARDIANCE, Veozah, REXULTI, Wegovy, TRELEGY ELLIPTA, BREZTRI, Dexcom G6 Transmitter.
Industry payments across CA — which companies pay providers there.
